The three histone deacetylase inhibitors on the market could be the leading edge of a wave, with more than a dozen candidates from the class in the clinic and a pool of potential indications that could widen beyond malignant cancers to central nervous system, inflammatory, metabolic and immunologic disorders.
HDAC Inhibitor Mysteries Remain As Candidates Advance
With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.